Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 169,700 shares, an increase of 7.3% from the March 31st total of 158,100 shares. Based on an average trading volume of 1,000 shares, the days-to-cover ratio is currently 169.7 days.

Genmab A/S Trading Down 0.5 %

Shares of GNMSF stock opened at $272.81 on Thursday. The stock has a 50 day moving average of $291.87 and a 200 day moving average of $297.60. Genmab A/S has a twelve month low of $262.00 and a twelve month high of $426.50.

Genmab A/S (OTCMKTS:GNMSF) last posted its quarterly earnings data on Wednesday, February 14th. The company reported $3.63 EPS for the quarter. The business had revenue of $675.29 million during the quarter. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.